Five biomarkers revealed as indicators of COVID-19 patient survival
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
List view / Grid view
News
Raman technique developed for high-throughput discovery of enzymes
A flow mode Raman-activated cell sorter called FlowRACS has been created by researchers for high-throughput discovery of enzymes and their cell factories.
Algorithm to predict sites of DNA methylation and drug targets developed
A machine learning algorithm that predicts sites of DNA methylation could aid in the identification of disease-causing mechanisms, say researchers.
Apilimod small molecule shows potent inhibition of SARS-CoV-2 in cells
Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
New α-radioimmunotherapy shows promise as multiple myeloma treatment in mice
An α-radioimmunotherapy called 212Pb-anti-CD38 was effective at preventing tumour growth and increasing survival in multiple myeloma tumour-bearing mice, a study has shown.
Largest sequencing study of SARS-CoV-2 presents six separate strains
Researchers have sequenced SARS-CoV-2, revealing at least six strains with little variability, useful information for vaccine developers.
Researchers identify promising drug target for Huntington’s disease
Researchers have found the TBK1 enzyme regulates the degradation and clearance of the huntingtin protein, making it a drug target for Huntington's disease.
Drug candidate for memory loss associated with Alzheimer’s developed
A drug called CMS121 given to mice with Alzheimer's-like disease treated their memory loss, allowing them to perform the same as healthy control mice in tests.
Decoy ACE2 receptors show promise as COVID-19 treatment in cell cultures
A new decoy receptor of ACE2 has been created which binds to and neutralises COVID-19 in live tissue cultures, preventing cells from becoming infected.
Researchers develop first synthetic inhibitor of coagulation factor XII
A new FXII inhibitor has been developed that efficiently blocked coagulation in a thrombosis model without increasing the risk of bleeding.
New chemical screening method could reveal molecular glue degraders
A phenotypic chemical screen has been developed that could be used to discover molecular glue degraders which induce the degradation of target proteins.
Protease inhibitors with antiviral activity against coronaviruses developed
Researchers have created compounds called 3C-like protease inhibitors which demonstrated antiviral activity against several coronaviruses in cells, including COVID-19.
Screening process may enhance mAb drug development, say scientists
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
Near-identical protein on SARS and COVID-19 could be targeted by FDA-approved drugs
According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
Altering protein in C. elegans offers hope for anti-ageing drugs
Researchers have been able to manipulate the lifespans of C. elegans by altering the VRK-1 protein, offering a potential target hope for anti-ageing drugs.